IRCT20210519051345N31
Recruiting
未知
Bioequivalence study of Empagliflozin 5/Metformin 500 mg tablet in healthy male volunteers using crossover design
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tabriz University of Medical Sciences
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General Health (in terms of Liver, Heart and Kidney)
- •Age between 18 to 59 years
Exclusion Criteria
- •History of cardiovascular disease, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Bioequivalence study of Empagliflozin 5 mg/ Metformin 1000 mg film coated tablet manufactured by Modava Pharmaceutical CompanyIRCT20130313012810N22Modava Pharmaceutical Company24
Recruiting
Not Applicable
Bioequivalence study of Empagliflozin/Metformin12.5/1000 mgThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N93Faran Pharmed company24
Recruiting
Not Applicable
Bioequivalence study of Empagliflozin Metformin 12.5-1000 mgBioequivalence study of Empagliflozin Metformin 12.5-1000 mg (Tehran Chemie Pharmaceutical Company) versus Synjiardy(Boehringer Ingelheim) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N17Tehran Chemie Pharmaceutical Company24
Recruiting
Phase 3
Comparison of the effect of Metformin and Empagliflozin in treatment of prediabetic patients.Prediabetes.Abnormal glucose tolerance testR73.0IRCT20210926052602N1Kashan University of Medical Sciences100
Recruiting
Not Applicable
Bioequivalence Study of Empagliflozin/Metformin 5/500 mgThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N95Kharazmi Pharmacy24